Aldevron and Inscripta ink manufacturing deal for CRISPR Type-V nuclease
A plan to broaden access to CRISPR has attracted a chunk of funding and is now seeing its wings spread.
Fargo-based DNA and mRNA producer Aldevron has signed an agreement with life sciences company Inscripta to manufacture and commercialize the Eureca-V Nuclease, a wild-type MAD7 CRISPR Type-V nuclease.
This partnership will aim to offer this nuclease as a standard research-grade and GMP catalog item. According to a press release, the production of Eureca-V is slated to start in Q3 of 2022. Financial details of the deal were not immediately made available to Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.